RxDoctor Payments Data

Margaret Duffy, MD

Nephrology · Allentown, PANPI 1518233881

Payments from drug & device makers

$1,210in general payments, 2019–2025

Across 27 payments — averaging $44.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aurinia Pharma U.S., Inc.$269
  • AstraZeneca$199
  • OPKO Pharmaceuticals, LLC$143
  • Amgen$125
  • Calliditas Therapeutics US Inc.$125
  • Otsuka America Pharmaceutical, Inc.$96
  • plus $254 from 8 others

What the payments were for

  • Food & beverage$1,09590%
  • Education$11610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,210 in reported general payments places this provider in the 60th percentile of 586 nephrology providers in Pennsylvania.

See all nephrology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$148,496
Medicare patients
568
Services billed
2,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol126$110,036
JardianceEmpagliflozin39$45,452
VeltassaPatiromer Calcium Sorbitex20$22,211
KerendiaFinerenone26$17,778
Lanthanum Carbonate12$8,834
Potassium Citrate ErPotassium Citrate30$4,140
Calcium Acetate56$2,698
Clonidine23$2,324
Eplerenone13$1,942
Sevelamer Carbonate20$1,918
Losartan Potassium114$1,501
Chlorthalidone36$855
Torsemide65$832
Valsartan23$743
Allopurinol42$658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$199$110,036126 claims
Boehringer IngelheimJardiance$40$45,45239 claims
BayerKerendia$37$17,77826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 586 nephrology providers in Pennsylvania.

Other nephrology in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →